Keywords: Novartis, Rasillamlo, Blood ressure, EU approval

Novartis gains EU approval for combo drug Rasilamlo to treat high BP

Article | 29 April 2011

Print This

Swiss drug major Novartis (NOVN: VX) says that Rasilamlo, a single-pill combination of aliskiren and amlodipine, has received approval from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in